Fujicalin®: Your Partner in Mitigating Nitrosamine Impurities in Drug Products

This newsletter by Fuji Chemical Industries highlights how Fujicalin®, a low nitrite content Dicalcium Phosphate Anhydrous (DCPA), can support manufacturers in mitigating these risks effectively.

THE ISSUES

The rise of nitrosamines in pharmaceuticals is a significant concern due to their potential cancer risk. The FDA has released updated guidelines urging manufacturers to actively manage the risks linked to nitrosamine impurities.

Regulatory Challenges:

The presence of nitrosamines can lead to regulatory actions including product recalls, stringent testing requirements, and the need for risk assessments, which can be costly and complex for pharmaceutical manufacturers.

Reputational Damage:

Companies facing issues with nitrosamine contamination can suffer from reputational damage, impacting consumer trust and potentially leading to decreased sales and market share.

THE TIMELINE

July 2018:
EMA recalls products containing Valsartan contaminated with NDMA.

September 2020:
FDA releases guidelines titled “Control of Nitrosamine Impurities in Human Drugs.”

September 2024:
FDA updates these guidelines to enforce stricter monitoring and mitigation strategies.

UNDERSTANDING N-NITROSAMINES IN PHARMACEUTICALS

Nitrosamines are classified as probable human carcinogens, posing a significant health risk as they can potentially lead to cancer when present in significant quantities over extended periods. The primary risk for the presence or formation of Nnitrosamines in drug products arises from the interplay of three critical factors:

Vulnerable Amines:
The presence of secondary or tertiary amines, which are more susceptible to nitrosation.

Nitrosating Agents:
The availability of nitrosating agents that can react with these amines to form N-nitrosamines.

Favorable Conditions:
Specific environmental conditions, such as elevated temperatures, acidic environments, and the presence of moisture in the liquid phase, which can facilitate the nitrosation process.

NITRITES IN EXCIPIENTS

Nitrite concentration varies by excipient chemistry, manufacturer, and batch.
Process water, raw materials, and processing conditions can introduce nitrites, but process water typically poses low risk, with levels usually below WHO limits.
While nitrites are present in many excipients, reducing them is challenging; complete elimination is impractical and alternatives like scavengers should be considered.
Each drug product should assess the potential risk of nitrites in its specific excipient.

STRATEGIC MEASURES TO MINIMIZE NITROSAMINE RISKS IN PHARMACEUTICAL MANUFACTURING

To effectively manage the risk of N-nitrosamines in drug formulations, manufacturers should implement control
strategies based on thorough risk assessments:

Nitrites Alone Are Not Sufficient:
The presence of nitrites in an excipient does not automatically lead to nitrosamine
formation; a vulnerable amine and specific reaction conditions are also required.

Excipient Contribution:
The nitrite contribution from an excipient depends on its quantity in the formulation,
highlighting the importance of careful selection.

Mitigation Strategies:
Manufacturers can reduce risks by using scavenger substances and minimizing moisture
through formulation, processing, and packaging techniques.

Collaborative Communication:
Open discussions between excipient suppliers and drug manufacturers are essential for
ensuring a clear understanding of excipient information and effective risk management.

RESPONSIBILITIES OF EXCIPIENT SUPPLIERS

To effectively manage the risk of N-nitrosamines in drug formulations, manufacturers should implement control strategies based on thorough risk assessments:

IPEC Questionnaire Assistance: The IPEC questionnaire helps excipient suppliers give detailed information about their products and the processes used to make them. This supports drug manufacturers in conducting thorough risk assessments.
Voluntary Testing: While not mandatory, excipient manufacturers can choose to test their products for N-Nitrosamines or nitrites and share the results if necessary.
Nitrites in Materials: Finding nitrites in materials, either current or from past batches, is not considered a defect. Standard Certificates of Analysis and Pharmacopeia tests usually do not check for this parameter.

Research indicates that approximately 40% of APIs could be potential nitrosamine precursors, particularly those containing secondary or tertiary amines, emphasizing the need for vigilant risk assessment and mitigation strategies in pharmaceutical formulations.

Fujicalin® – A Strategic Solution

Fujicalin® is a specialized excipient that enhances tablet formulations while reducing nitrosamine formation risk. Its low nitrite content prevents harmful impurities, and its high specific surface area from a patented spray-drying process improves blending and uniformity. Fujicalin® also provides excellent flow and compression properties, enabling robust tablet production and reducing equipment wear.

The APIs that are prone to nitrosamine formation:

1. Cardiovascular Medications

Beta Adrenoreceptor Blockers and Beta Agonists: Propranolol, Atenolol, Bisoprolol, Metoprolol
ACE Inhibitors: Enalapril, Ramipril, Quinapril, Lisinopril

2. Migraine Treatments

Triptans: Sumatriptan, Rizatriptan, Naratriptan, Almotriptan

3. Gastrointestinal Medications

H2 Blockers: Ranitidine, Nizatidine

4. Diabetes Management

Antidiabetics: Metformin

5. Miscellaneous APIs

Sitagliptin, Verenicline, etc.

Please contact us to know the detailed list of APIs prone to nitrosamine formation.

Fujicalin® – 3 Key Benefits

Low Nitrite Content

Reduces the risk of harmful nitrosamines by maintaining low nitrite levels.

High Specific Surface Area

Its unique spray-drying process creates porous spheres, enhancing blending and uniformity in formulations.

Excellent Flow and Compression Characteristics

Produces strong tablets with minimal abrasion on tableting machines, ensuring smoother operations and less equipment wear.

SUMMARY

Fujicalin® is your ultimate ally in the fight against nitrosamine risks in drug formulations. As a leading excipient, it provides a low-risk solution for manufacturers seeking to ensure the safety of their products. By partnering with Fuji Chemical Industries, you can access comprehensive nitrosamine risk assessments tailored specifically for Fujicalin®, empowering you to make informed decisions that prioritize patient safety.

What sets Fujicalin® apart? Rigorous Testing and Compliance. Fuji Chemical Industries stays ahead of the curve by continuously monitoring regulatory changes and conducting thorough tests for nitrate and nitrite content in Fujicalin®. Utilizing ion chromatography, a trusted analytical method, we confirm that Fujicalin® contains extremely low levels of nitrates and nitrites, further minimizing the risk of nitrosamine formation.

With Fujicalin®, you gain peace of mind knowing that no raw materials containing amines or nitrosating agents are used in its production. This commitment to quality means that you can confidently incorporate Fujicalin® into your formulations, knowing it meets the highest safety standards.

Choose Fujicalin® – where innovation meets safety.

Continue reading and see the full Pharmaceutical Technical Newsletter on Fujicalin®: Your Partner in Mitigating Nitrosamine Impurities in Drug Products here:

(click the picture to download the technical newsletter)

Do you need more information or a sample of Fuji Chemical Industries excipients?

Name *

First

Last

Email *

Company *

Address

Address Line 1

Address Line 2

City

State / Province / Region

Postal Code

Country

Comment or Message *

I agree with the privacy policy as per https://www.pharmaexcipients.com/privacy/ . The contact details will be shared with the supplier who holds the request above. The supplier can contact you directly.

Message